Patients with cystic fibrosis (CF) who carry certain mutations in the HFE…
Articles by Ana Pena, PhD
Symkevi (tezacaftor/ivacaftor combo), by Vertex Pharmaceuticals, has been approved in the European Union for patients with cystic fibrosis (CF) ages 12 or…
A Phase 1b/2a, dose-escalating clinical trial evaluating the effects of POL6014 in patients…
Adding the investigational therapy VX-445 to tezacaftor (VX-661) and Kalydeco (ivacaftor) led to a roughly 10 percent…
Once-daily acebilustat, an investigational oral therapy for cystic fibrosis (CF) under development by…
Santhera Pharmaceuticals’ investigative inhalation therapy for cystic fibrosis (CF), POL6014, has been favored…
Two compounds that make up approved cystic fibrosis (CF) therapy Orkambi — lumacaftor and ivacaftor — may work…
Researchers may have found a new way of treating antibiotic-resistant bacterial infections, specifically Pseudomonas aeruginosa…
Consuming dietary flavonoids — compounds naturally found in fruits, vegetables, chocolate, and beverages like…
A new electronic nose, called Aeonose, was seen to be a feasible, accurate…